Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.
Do you have standard first-line and second-line treatment recommendations for patients that are nonresponsive to topical treatments? How important is patient input in choosing a treatment method?